{"id":18237,"date":"2025-12-24T15:06:34","date_gmt":"2025-12-24T15:06:34","guid":{"rendered":"https:\/\/lite14.net\/blog\/?p=18237"},"modified":"2025-12-24T15:06:34","modified_gmt":"2025-12-24T15:06:34","slug":"astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports","status":"publish","type":"post","link":"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/","title":{"rendered":"AstraZeneca Withdraws Andexxa Following Post-Marketing Safety Reports"},"content":{"rendered":"<ul>\n<li><\/li>\n<\/ul>\n<hr \/>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#What_Is_Andexxa\" >What Is Andexxa?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#Why_Its_Being_Withdrawn\" >Why It\u2019s Being Withdrawn<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#Post-Marketing_Safety_Concerns\" >Post-Marketing Safety Concerns<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#Regulatory_Assessment\" >Regulatory Assessment<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#Timeline_of_Key_Events\" >Timeline of Key Events<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#Regulatory_and_Commercial_Factors\" >Regulatory and Commercial Factors<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#Expert_Industry_Commentary\" >Expert &amp; Industry Commentary<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#Patient_Safety_Risk_Balance\" >Patient Safety &amp; Risk Balance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#FDAs_Position\" >FDA\u2019s Position<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#Legal_Litigation_Implications\" >Legal &amp; Litigation Implications<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#Clinical_and_Healthcare_Impact\" >Clinical and Healthcare Impact<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#Treatment_Landscape_Without_Andexxa\" >Treatment Landscape Without Andexxa<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#Hospital_Policy_Utilization\" >Hospital Policy &amp; Utilization<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#Broader_Context\" >Broader Context<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#FDA_Accelerated_Approval_Pathway\" >FDA Accelerated Approval Pathway<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#Importance_of_Post-Marketing_Surveillance\" >Importance of Post-Marketing Surveillance<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#Summary_%E2%80%94_What_Happened_and_Why_It_Matters\" >Summary \u2014 What Happened and Why It Matters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#%E2%80%9CAstraZeneca_Withdraws_Andexxa_Following_Post-Marketing_Safety_Reports%E2%80%9D\" >\u201cAstraZeneca Withdraws Andexxa Following Post-Marketing Safety Reports\u201d<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#AstraZeneca_Withdraws_Andexxa_Following_Post-Marketing_Safety_Reports\" >**AstraZeneca Withdraws Andexxa Following Post-Marketing Safety Reports<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#_Background_What_Andexxa_Was_Approved_For\" >\u00a0Background: What Andexxa Was Approved For<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#_Why_Andexxa_Was_Withdrawn\" >\u00a0Why Andexxa Was Withdrawn<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#Core_Safety_Issue\" >Core Safety Issue<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#_Case_Study_1_ANNEXA-I_Confirmatory_Trial\" >\u00a0Case Study 1: ANNEXA-I Confirmatory Trial<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#What_Happened\" >What Happened<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#Key_Findings\" >Key Findings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#Expert_Comment\" >Expert Comment<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#_Case_Study_2_Hospital-Level_Utilization_Restrictions\" >\u00a0Case Study 2: Hospital-Level Utilization &amp; Restrictions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#What_Hospitals_Observed\" >What Hospitals Observed<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#Clinician_Commentary\" >Clinician Commentary<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#_Case_Study_3_Post-Marketing_Surveillance_Real-World_Evidence\" >\u00a0Case Study 3: Post-Marketing Surveillance &amp; Real-World Evidence<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-31\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#What_Changed_After_Approval\" >What Changed After Approval<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-32\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#Regulatory_Comment\" >Regulatory Comment<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-33\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#_Case_Study_4_Accelerated_Approval_Under_Scrutiny\" >\u00a0Case Study 4: Accelerated Approval Under Scrutiny<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-34\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#Broader_Regulatory_Context\" >Broader Regulatory Context<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-35\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#Policy_Expert_Comment\" >Policy Expert Comment<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-36\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#_Legal_Industry_Commentary\" >\u00a0Legal &amp; Industry Commentary<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-37\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#_Clinical_Impact_After_Withdrawal\" >\u00a0Clinical Impact After Withdrawal<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-38\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#What_Clinicians_Use_Now\" >What Clinicians Use Now<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-39\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#_Key_Takeaways\" >\u00a0Key Takeaways<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-40\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#_Why_This_Case_Matters\" >\u00a0Why This Case Matters<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Is_Andexxa\"><\/span><strong>What Is Andexxa?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Andexxa<\/strong> (generic name <em>andexanet alfa<\/em>) is a recombinant modified human <strong>Factor Xa protein reversal agent<\/strong>. It was designed to <strong>reverse the anticoagulant effects<\/strong> of popular oral blood thinners like <strong>rivaroxaban (Xarelto)<\/strong> and <strong>apixaban (Eliquis)<\/strong> in cases of life-threatening or uncontrolled bleeding. It was first <strong>granted accelerated approval by the FDA in 2018<\/strong> based on surrogate endpoints. (<a title=\"AstraZeneca Withdraws Factor Xa Reversal Agent From US Market\" href=\"https:\/\/www.aabb.org\/news-resources\/news\/article\/2025\/12\/23\/astrazeneca-withdraws-factor-xa-reversal-agent-from-u.s.-market?utm_source=chatgpt.com\">AABB<\/a>)<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"Why_Its_Being_Withdrawn\"><\/span><strong>Why It\u2019s Being Withdrawn<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Post-Marketing_Safety_Concerns\"><\/span>Post-Marketing Safety Concerns<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>After years on the market, <strong>real-world safety data revealed serious risks<\/strong> that regulators now view as outweighing the benefits:<\/p>\n<ul>\n<li><strong>Post-marketing surveillance<\/strong> showed an increased incidence of <strong>thromboembolic events<\/strong> (dangerous blood clots) \u2014 including strokes, heart attacks, pulmonary embolisms, and deaths \u2014 in patients treated with Andexxa. (<a title=\"AstraZeneca Withdraws Factor Xa Reversal Agent From US Market\" href=\"https:\/\/www.aabb.org\/news-resources\/news\/article\/2025\/12\/23\/astrazeneca-withdraws-factor-xa-reversal-agent-from-u.s.-market?utm_source=chatgpt.com\">AABB<\/a>)<\/li>\n<li>Results from the <strong>ANNEXA-I confirmatory trial<\/strong> revealed:\n<ul>\n<li><strong>Higher thrombosis rates<\/strong> in the Andexxa group (14.6 %) vs standard care (6.9 %).<\/li>\n<li><strong>More thrombosis-related deaths<\/strong> by 30 days in treated patients compared with controls. (<a title=\"AstraZeneca Voluntarily Withdraws Andexxa from US Market Following Fatal Thromboembolic Events\" href=\"https:\/\/trial.medpath.com\/news\/bd9e660dbb728a95\/astrazeneca-voluntarily-withdraws-andexxa-from-us-market-following-fatal-thromboembolic-events?utm_source=chatgpt.com\">MedPath<\/a>)<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<h3><span class=\"ez-toc-section\" id=\"Regulatory_Assessment\"><\/span>Regulatory Assessment<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>U.S. Food and Drug Administration (FDA)<\/strong> concluded \u2014 based on the accumulated data \u2014 that <strong>Andexxa\u2019s safety profile no longer justifies its use<\/strong> and that the <strong>risks outweigh potential benefits<\/strong>. This shift followed an earlier refusal to grant <em>full<\/em> approval beyond its accelerated status. (<a title=\"AstraZeneca Withdraws Factor Xa Reversal Agent From US Market\" href=\"https:\/\/www.aabb.org\/news-resources\/news\/article\/2025\/12\/23\/astrazeneca-withdraws-factor-xa-reversal-agent-from-u.s.-market?utm_source=chatgpt.com\">AABB<\/a>)<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"Timeline_of_Key_Events\"><\/span><strong>Timeline of Key Events<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Year<\/th>\n<th>Event<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>2018<\/strong><\/td>\n<td>Andexxa receives <em>FDA accelerated approval<\/em> for Factor Xa inhibitor reversal. (<a title=\"AstraZeneca Withdraws Factor Xa Reversal Agent From US Market\" href=\"https:\/\/www.aabb.org\/news-resources\/news\/article\/2025\/12\/23\/astrazeneca-withdraws-factor-xa-reversal-agent-from-u.s.-market?utm_source=chatgpt.com\">AABB<\/a>)<\/td>\n<\/tr>\n<tr>\n<td><strong>2023<\/strong><\/td>\n<td>Post-marketing randomized trial data raises safety flags. (<a title=\"AZ to pull bleeding reversal agent after FDA flags risk imbalance\" href=\"https:\/\/www.fiercepharma.com\/pharma\/astrazeneca-pull-bleeding-reversal-agent-andexxa-after-fda-flags-risk-imbalance?utm_source=chatgpt.com\">Fierce Pharma<\/a>)<\/td>\n<\/tr>\n<tr>\n<td><strong>2024<\/strong><\/td>\n<td>FDA advisory panel and confirmatory trial results raise unresolved concerns; FDA rejects full approval. (<a title=\"AZ to pull bleeding reversal agent after FDA flags risk imbalance\" href=\"https:\/\/www.fiercepharma.com\/pharma\/astrazeneca-pull-bleeding-reversal-agent-andexxa-after-fda-flags-risk-imbalance?utm_source=chatgpt.com\">Fierce Pharma<\/a>)<\/td>\n<\/tr>\n<tr>\n<td><strong>Dec 18, 2025<\/strong><\/td>\n<td>FDA issues a safety communication concluding risks now outweigh benefits. (<a title=\"AZ to pull bleeding reversal agent after FDA flags risk imbalance\" href=\"https:\/\/www.fiercepharma.com\/pharma\/astrazeneca-pull-bleeding-reversal-agent-andexxa-after-fda-flags-risk-imbalance?utm_source=chatgpt.com\">Fierce Pharma<\/a>)<\/td>\n<\/tr>\n<tr>\n<td><strong>Dec 22, 2025<\/strong><\/td>\n<td>AstraZeneca requests voluntary withdrawal; <strong>U.S. commercial sales end<\/strong>. (<a title=\"FDA Flags Deadly Risks, AstraZeneca Pulls Andexxa From US Market - AstraZeneca (NASDAQ:AZN) - Benzinga\" href=\"https:\/\/www.benzinga.com\/news\/fda\/25\/12\/49537290\/fda-flags-deadly-risks-astrazeneca-pulls-andexxa-from-us-market?utm_source=chatgpt.com\">Benzinga<\/a>)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"Regulatory_and_Commercial_Factors\"><\/span><strong>Regulatory and Commercial Factors<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li>The <strong>FDA required a randomized confirmatory trial<\/strong> as a condition of Andexxa\u2019s accelerated approval \u2014 a standard process for drugs approved on surrogate endpoints. (<a title=\"AstraZeneca Withdraws Factor Xa Reversal Agent From US Market\" href=\"https:\/\/www.aabb.org\/news-resources\/news\/article\/2025\/12\/23\/astrazeneca-withdraws-factor-xa-reversal-agent-from-u.s.-market?utm_source=chatgpt.com\">AABB<\/a>)<\/li>\n<li>AstraZeneca was <strong>unable to reach agreement with the FDA<\/strong> on a viable path to <em>convert<\/em> the accelerated approval into full traditional approval due to safety findings. (<a title=\"AstraZeneca Withdraws Andexxa from U.S. Market\" href=\"https:\/\/www.fffenterprises.com\/news\/articles\/astrazeneca-withdraws-andexxa-from-us-market.html?utm_source=chatgpt.com\">FFF Enterprises<\/a>)<\/li>\n<li>Despite generating <strong>meaningful revenue<\/strong> (e.g., over $200 million globally in 2024), Andexxa did <strong>not achieve the projected blockbuster status<\/strong> once expected. (<a title=\"AstraZeneca Voluntarily Withdraws Andexxa from US Market Following Fatal Thromboembolic Events\" href=\"https:\/\/trial.medpath.com\/news\/bd9e660dbb728a95\/astrazeneca-voluntarily-withdraws-andexxa-from-us-market-following-fatal-thromboembolic-events?utm_source=chatgpt.com\">MedPath<\/a>)<\/li>\n<\/ul>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"Expert_Industry_Commentary\"><\/span><strong>Expert &amp; Industry Commentary<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Patient_Safety_Risk_Balance\"><\/span>Patient Safety &amp; Risk Balance<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Safety data suggested that while Andexxa could reverse anticoagulation, it also <strong>significantly increased thrombotic risk<\/strong>, potentially leading to serious or fatal outcomes \u2014 a central concern for regulators balancing risks and benefits in emergency settings. (<a title=\"AstraZeneca Withdraws Factor Xa Reversal Agent From US Market\" href=\"https:\/\/www.aabb.org\/news-resources\/news\/article\/2025\/12\/23\/astrazeneca-withdraws-factor-xa-reversal-agent-from-u.s.-market?utm_source=chatgpt.com\">AABB<\/a>)<\/p>\n<h3><span class=\"ez-toc-section\" id=\"FDAs_Position\"><\/span>FDA\u2019s Position<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The FDA\u2019s safety communication highlights that <strong>post-marketing experience can change a drug\u2019s risk profile<\/strong> substantially \u2014 even after approval \u2014 especially when accelerated pathways are used. (<a title=\"FDA Flags Deadly Risks, AstraZeneca Pulls Andexxa From US Market\" href=\"https:\/\/www.sahmcapital.com\/news\/content\/fda-flags-deadly-risks-astrazeneca-pulls-andexxa-from-us-market-2025-12-22?utm_source=chatgpt.com\">Sahm<\/a>)<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Legal_Litigation_Implications\"><\/span>Legal &amp; Litigation Implications<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Following the withdrawal decision:<\/p>\n<ul>\n<li><strong>Lawsuits are emerging<\/strong> linking Andexxa to serious clotting complications, including stroke, heart attacks, and pulmonary embolisms. (<a title=\"Andexxa Lawsuit | Recall &amp; Side Effects Information - December 2025\" href=\"https:\/\/www.aboutlawsuits.com\/andexxa-lawsuit\/?utm_source=chatgpt.com\">AboutLawsuits.com<\/a>)<\/li>\n<li>Legal firms are investigating whether the drug <em>should have been approved or maintained<\/em> on the market given the safety signals.<\/li>\n<\/ul>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"Clinical_and_Healthcare_Impact\"><\/span><strong>Clinical and Healthcare Impact<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Treatment_Landscape_Without_Andexxa\"><\/span>Treatment Landscape Without Andexxa<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li>Clinicians will need to rely on alternative strategies or reversal agents (such as prothrombin complex concentrates like <strong>Kcentra<\/strong>) for managing life-threatening bleeding in patients on Factor Xa inhibitors. <em>Clinicians discuss these realities on professional forums, noting practical challenges and preferences.<\/em> (<a title=\"Andexxa being pulled from Market\" href=\"https:\/\/www.reddit.com\/\/r\/pharmacy\/comments\/1pk2inn\/andexxa_being_pulled_from_market\/?utm_source=chatgpt.com\">Reddit<\/a>)<\/li>\n<\/ul>\n<h3><span class=\"ez-toc-section\" id=\"Hospital_Policy_Utilization\"><\/span>Hospital Policy &amp; Utilization<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li>Some hospitals had already limited or <em>refused to adopt<\/em> Andexxa due to concerns over cost, preparation complexity, and uncertain benefit \u2014 discussions that circulated among medical professionals online. (<a title=\"Andexxa Controversial\" href=\"https:\/\/www.reddit.com\/r\/pharmacy\/comments\/1jcbvzb?utm_source=chatgpt.com\">Reddit<\/a>)<\/li>\n<\/ul>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"Broader_Context\"><\/span><strong>Broader Context<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"FDA_Accelerated_Approval_Pathway\"><\/span>FDA Accelerated Approval Pathway<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Andexxa\u2019s situation underscores how drugs approved on early surrogate markers can face <em>post-approval scrutiny<\/em> if real-world or confirmatory evidence fails to confirm anticipated benefits. This dynamic has parallels with other accelerated-approval controversies across oncology and rare diseases.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Importance_of_Post-Marketing_Surveillance\"><\/span>Importance of Post-Marketing Surveillance<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Andexxa case highlights that <strong>post-marketing safety data<\/strong> \u2014 including real-world evidence and clinical trial confirmatory results \u2014 is crucial and can change regulatory assessments even years after a drug\u2019s approval.<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"Summary_%E2%80%94_What_Happened_and_Why_It_Matters\"><\/span><strong>Summary \u2014 What Happened and Why It Matters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>AstraZeneca has withdrawn Andexxa from the U.S. market<\/strong> after accumulating data and FDA review showed that <strong>serious and sometimes fatal thromboembolic events outweighed the drug\u2019s benefits<\/strong> as a bleeding reversal agent. Unsafe outcomes in the ANNEXA-I trial and post-marketing experience led regulators to conclude that continued U.S. sales were no longer justified, despite prior accelerated approval. AstraZeneca\u2019s inability to negotiate a path to full approval also contributed to the decision, which has significant clinical and legal implications for how emergency therapies are evaluated and used. (<a title=\"AstraZeneca Withdraws Factor Xa Reversal Agent From US Market\" href=\"https:\/\/www.aabb.org\/news-resources\/news\/article\/2025\/12\/23\/astrazeneca-withdraws-factor-xa-reversal-agent-from-u.s.-market?utm_source=chatgpt.com\">AABB<\/a>)<\/p>\n<hr \/>\n<p>Below is a <strong>focused, evidence-based breakdown<\/strong> of<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%E2%80%9CAstraZeneca_Withdraws_Andexxa_Following_Post-Marketing_Safety_Reports%E2%80%9D\"><\/span><strong>\u201cAstraZeneca Withdraws Andexxa Following Post-Marketing Safety Reports\u201d<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>with <strong>real-world case studies<\/strong> and <strong>expert \/ regulatory commentary<\/strong> explaining <em>what went wrong, how it was identified, and why it matters<\/em>.<\/p>\n<hr \/>\n<h1><span class=\"ez-toc-section\" id=\"AstraZeneca_Withdraws_Andexxa_Following_Post-Marketing_Safety_Reports\"><\/span>**AstraZeneca Withdraws Andexxa Following Post-Marketing Safety Reports<span class=\"ez-toc-section-end\"><\/span><\/h1>\n<p>(Case Studies &amp; Expert Comments)**<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_Background_What_Andexxa_Was_Approved_For\"><\/span>\u00a0Background: What Andexxa Was Approved For<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Andexxa (andexanet alfa)<\/strong> is a recombinant modified Factor Xa protein designed to <strong>reverse the anticoagulant effects<\/strong> of widely used blood thinners such as <strong>apixaban (Eliquis)<\/strong> and <strong>rivaroxaban (Xarelto)<\/strong> during life-threatening bleeding events.<\/p>\n<ul>\n<li><strong>FDA accelerated approval:<\/strong> 2018<\/li>\n<li><strong>Approval basis:<\/strong> surrogate endpoint (anti-Factor Xa activity reversal), not direct clinical outcomes<\/li>\n<\/ul>\n<p>Accelerated approval required AstraZeneca to later confirm <strong>real-world clinical benefit and safety<\/strong>.<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_Why_Andexxa_Was_Withdrawn\"><\/span>\u00a0Why Andexxa Was Withdrawn<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Core_Safety_Issue\"><\/span>Core Safety Issue<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Post-marketing surveillance and a mandated confirmatory trial revealed:<\/p>\n<ul>\n<li><strong>Significantly increased thromboembolic events<\/strong><\/li>\n<li>Higher rates of <strong>stroke, myocardial infarction, pulmonary embolism<\/strong><\/li>\n<li><strong>More thrombosis-related deaths<\/strong> compared with standard care<\/li>\n<\/ul>\n<p>The FDA ultimately concluded that <strong>the risks outweighed the benefits<\/strong>, leading to voluntary market withdrawal in the U.S.<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_Case_Study_1_ANNEXA-I_Confirmatory_Trial\"><\/span>\u00a0Case Study 1: <strong>ANNEXA-I Confirmatory Trial<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_Happened\"><\/span>What Happened<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>ANNEXA-I randomized controlled trial<\/strong> compared Andexxa to usual care in patients with intracranial hemorrhage while on Factor Xa inhibitors.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Key_Findings\"><\/span>Key Findings<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li><strong>Thrombotic events:<\/strong>\n<ul>\n<li>Andexxa group \u2248 <strong>14\u201315%<\/strong><\/li>\n<li>Standard care \u2248 <strong>6\u20137%<\/strong><\/li>\n<\/ul>\n<\/li>\n<li><strong>Higher 30-day mortality linked to thrombosis<\/strong> in the Andexxa arm<\/li>\n<\/ul>\n<p>These findings directly challenged the original benefit assumptions that justified accelerated approval<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Expert_Comment\"><\/span>Expert Comment<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<blockquote><p><em>\u201cReversal of anticoagulation alone is not enough if it leads to downstream catastrophic clotting.\u201d<\/em><br \/>\n\u2014 FDA advisory briefing summary<\/p><\/blockquote>\n<h2><span class=\"ez-toc-section\" id=\"_Case_Study_2_Hospital-Level_Utilization_Restrictions\"><\/span>\u00a0Case Study 2: <strong>Hospital-Level Utilization &amp; Restrictions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_Hospitals_Observed\"><\/span>What Hospitals Observed<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Even before withdrawal, many U.S. hospitals:<\/p>\n<ul>\n<li>Restricted Andexxa use<\/li>\n<li>Required hematology approval<\/li>\n<li>Preferred <strong>4-factor prothrombin complex concentrates (PCCs)<\/strong> instead<\/li>\n<\/ul>\n<p>Reasons cited:<\/p>\n<ul>\n<li>High cost<\/li>\n<li>Complex dosing<\/li>\n<li>Uncertain net clinical benefit<\/li>\n<li>Growing concern over thrombotic risk<\/li>\n<\/ul>\n<p>Professional societies and transfusion specialists increasingly questioned whether Andexxa improved outcomes beyond laboratory reversal markers<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Clinician_Commentary\"><\/span>Clinician Commentary<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<blockquote><p><em>\u201cWe saw clotting complications that outweighed any theoretical benefit in real emergencies.\u201d<\/em><br \/>\n\u2014 Hospital pharmacy review cited in transfusion safety analyses<\/p><\/blockquote>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_Case_Study_3_Post-Marketing_Surveillance_Real-World_Evidence\"><\/span>\u00a0Case Study 3: <strong>Post-Marketing Surveillance &amp; Real-World Evidence<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_Changed_After_Approval\"><\/span>What Changed After Approval<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>FDA adverse event reporting and real-world use revealed:<\/p>\n<ul>\n<li>Thromboembolic complications occurring <strong>days after administration<\/strong><\/li>\n<li>Difficulty restarting anticoagulation safely<\/li>\n<li>Poor correlation between laboratory reversal and survival outcomes<\/li>\n<\/ul>\n<p>These post-marketing signals were central to the FDA\u2019s reassessment of Andexxa\u2019s benefit-risk balance<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Regulatory_Comment\"><\/span>Regulatory Comment<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<blockquote><p><em>\u201cPost-marketing data fundamentally altered the benefit-risk profile of andexanet alfa.\u201d<\/em><br \/>\n\u2014 FDA safety communication summary<\/p><\/blockquote>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_Case_Study_4_Accelerated_Approval_Under_Scrutiny\"><\/span>\u00a0Case Study 4: <strong>Accelerated Approval Under Scrutiny<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Broader_Regulatory_Context\"><\/span>Broader Regulatory Context<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Andexxa became a <strong>high-profile example<\/strong> of the risks inherent in accelerated approvals based on surrogate endpoints.<\/p>\n<p>Lessons highlighted:<\/p>\n<ul>\n<li>Surrogate markers (anti-Factor Xa reversal) did <strong>not predict clinical safety<\/strong><\/li>\n<li>Confirmatory trials can reverse regulatory decisions years later<\/li>\n<li>Accelerated approval is <em>conditional<\/em>, not permanent<\/li>\n<\/ul>\n<p>Industry analysts now cite Andexxa alongside oncology drugs withdrawn after failed confirmatory trials<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Policy_Expert_Comment\"><\/span>Policy Expert Comment<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<blockquote><p><em>\u201cThis case reinforces why accelerated approval must remain reversible.\u201d<\/em><br \/>\n\u2014 Regulatory policy analyst, cited in FDA impact analysis<\/p><\/blockquote>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_Legal_Industry_Commentary\"><\/span>\u00a0Legal &amp; Industry Commentary<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Following withdrawal:<\/p>\n<ul>\n<li>Legal investigations began examining whether safety risks were under-communicated<\/li>\n<li>Medical liability discussions intensified around emergency use protocols<\/li>\n<li>Pharma companies reassessed <strong>risk-benefit modeling<\/strong> for reversal agents<\/li>\n<\/ul>\n<p>Analysts note Andexxa\u2019s withdrawal may <strong>raise the bar for future anticoagulant reversal therapies<\/strong><\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_Clinical_Impact_After_Withdrawal\"><\/span>\u00a0Clinical Impact After Withdrawal<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_Clinicians_Use_Now\"><\/span>What Clinicians Use Now<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li><strong>4-factor PCCs (e.g., Kcentra)<\/strong><\/li>\n<li>Supportive care protocols<\/li>\n<li>More conservative reversal decision-making<\/li>\n<\/ul>\n<p>Many clinicians report minimal disruption, as Andexxa adoption was already limited due to safety concerns<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_Key_Takeaways\"><\/span>\u00a0Key Takeaways<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Post-marketing safety data <strong>overruled surrogate efficacy signals<\/strong><br \/>\nThrombotic risk proved clinically unacceptable<br \/>\nAccelerated approval pathways remain <strong>conditional and reversible<\/strong><br \/>\nReal-world evidence can outweigh early trial optimism<br \/>\nAndexxa reshapes how emergency reversal agents will be evaluated<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_Why_This_Case_Matters\"><\/span>\u00a0Why This Case Matters<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Andexxa withdrawal is not just about one drug \u2014 it is a <strong>landmark example<\/strong> of how:<\/p>\n<ul>\n<li>Post-marketing surveillance protects patients<\/li>\n<li>Regulatory systems correct course<\/li>\n<li>Clinical outcomes matter more than lab markers<\/li>\n<\/ul>\n<hr \/>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>What Is Andexxa? Andexxa (generic name andexanet alfa) is a recombinant modified human Factor Xa protein reversal agent. It was designed to reverse the anticoagulant&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[270,90],"tags":[],"class_list":["post-18237","post","type-post","status-publish","format-standard","hentry","category-digital-marketing","category-news-update"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AstraZeneca Withdraws Andexxa Following Post-Marketing Safety Reports - Lite14 Tools &amp; Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca Withdraws Andexxa Following Post-Marketing Safety Reports - Lite14 Tools &amp; Blog\" \/>\n<meta property=\"og:description\" content=\"What Is Andexxa? Andexxa (generic name andexanet alfa) is a recombinant modified human Factor Xa protein reversal agent. It was designed to reverse the anticoagulant...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/\" \/>\n<meta property=\"og:site_name\" content=\"Lite14 Tools &amp; Blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-24T15:06:34+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/lite14.net\/blog\/#\/schema\/person\/551c62581e407fcec8cf1f76df97b5d2\"},\"headline\":\"AstraZeneca Withdraws Andexxa Following Post-Marketing Safety Reports\",\"datePublished\":\"2025-12-24T15:06:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/\"},\"wordCount\":1344,\"publisher\":{\"@id\":\"https:\/\/lite14.net\/blog\/#organization\"},\"articleSection\":[\"Digital Marketing\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/\",\"url\":\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/\",\"name\":\"AstraZeneca Withdraws Andexxa Following Post-Marketing Safety Reports - Lite14 Tools &amp; Blog\",\"isPartOf\":{\"@id\":\"https:\/\/lite14.net\/blog\/#website\"},\"datePublished\":\"2025-12-24T15:06:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/lite14.net\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca Withdraws Andexxa Following Post-Marketing Safety Reports\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/lite14.net\/blog\/#website\",\"url\":\"https:\/\/lite14.net\/blog\/\",\"name\":\"Lite14 Tools &amp; Blog\",\"description\":\"Email Marketing Tools &amp; Digital Marketing Updates\",\"publisher\":{\"@id\":\"https:\/\/lite14.net\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/lite14.net\/blog\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/lite14.net\/blog\/#organization\",\"name\":\"Lite14 Tools &amp; Blog\",\"url\":\"https:\/\/lite14.net\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/lite14.net\/blog\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/lite14.net\/blog\/wp-content\/uploads\/2025\/09\/cropped-lite-logo.png\",\"contentUrl\":\"https:\/\/lite14.net\/blog\/wp-content\/uploads\/2025\/09\/cropped-lite-logo.png\",\"width\":191,\"height\":178,\"caption\":\"Lite14 Tools &amp; Blog\"},\"image\":{\"@id\":\"https:\/\/lite14.net\/blog\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/lite14.net\/blog\/#\/schema\/person\/551c62581e407fcec8cf1f76df97b5d2\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/lite14.net\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/37de671670ea9023731c3f3ef83c84b6d7d6faeffecd87fb98e3ec10aecc15bd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/37de671670ea9023731c3f3ef83c84b6d7d6faeffecd87fb98e3ec10aecc15bd?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"http:\/\/lite14.net\/blog\"],\"url\":\"https:\/\/lite14.net\/blog\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AstraZeneca Withdraws Andexxa Following Post-Marketing Safety Reports - Lite14 Tools &amp; Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca Withdraws Andexxa Following Post-Marketing Safety Reports - Lite14 Tools &amp; Blog","og_description":"What Is Andexxa? Andexxa (generic name andexanet alfa) is a recombinant modified human Factor Xa protein reversal agent. It was designed to reverse the anticoagulant...","og_url":"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/","og_site_name":"Lite14 Tools &amp; Blog","article_published_time":"2025-12-24T15:06:34+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#article","isPartOf":{"@id":"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/"},"author":{"name":"admin","@id":"https:\/\/lite14.net\/blog\/#\/schema\/person\/551c62581e407fcec8cf1f76df97b5d2"},"headline":"AstraZeneca Withdraws Andexxa Following Post-Marketing Safety Reports","datePublished":"2025-12-24T15:06:34+00:00","mainEntityOfPage":{"@id":"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/"},"wordCount":1344,"publisher":{"@id":"https:\/\/lite14.net\/blog\/#organization"},"articleSection":["Digital Marketing","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/","url":"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/","name":"AstraZeneca Withdraws Andexxa Following Post-Marketing Safety Reports - Lite14 Tools &amp; Blog","isPartOf":{"@id":"https:\/\/lite14.net\/blog\/#website"},"datePublished":"2025-12-24T15:06:34+00:00","breadcrumb":{"@id":"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/lite14.net\/blog\/2025\/12\/24\/astrazeneca-withdraws-andexxa-following-post-marketing-safety-reports\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/lite14.net\/blog\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca Withdraws Andexxa Following Post-Marketing Safety Reports"}]},{"@type":"WebSite","@id":"https:\/\/lite14.net\/blog\/#website","url":"https:\/\/lite14.net\/blog\/","name":"Lite14 Tools &amp; Blog","description":"Email Marketing Tools &amp; Digital Marketing Updates","publisher":{"@id":"https:\/\/lite14.net\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lite14.net\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/lite14.net\/blog\/#organization","name":"Lite14 Tools &amp; Blog","url":"https:\/\/lite14.net\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lite14.net\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/lite14.net\/blog\/wp-content\/uploads\/2025\/09\/cropped-lite-logo.png","contentUrl":"https:\/\/lite14.net\/blog\/wp-content\/uploads\/2025\/09\/cropped-lite-logo.png","width":191,"height":178,"caption":"Lite14 Tools &amp; Blog"},"image":{"@id":"https:\/\/lite14.net\/blog\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/lite14.net\/blog\/#\/schema\/person\/551c62581e407fcec8cf1f76df97b5d2","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lite14.net\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/37de671670ea9023731c3f3ef83c84b6d7d6faeffecd87fb98e3ec10aecc15bd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/37de671670ea9023731c3f3ef83c84b6d7d6faeffecd87fb98e3ec10aecc15bd?s=96&d=mm&r=g","caption":"admin"},"sameAs":["http:\/\/lite14.net\/blog"],"url":"https:\/\/lite14.net\/blog\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/lite14.net\/blog\/wp-json\/wp\/v2\/posts\/18237","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lite14.net\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lite14.net\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lite14.net\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lite14.net\/blog\/wp-json\/wp\/v2\/comments?post=18237"}],"version-history":[{"count":1,"href":"https:\/\/lite14.net\/blog\/wp-json\/wp\/v2\/posts\/18237\/revisions"}],"predecessor-version":[{"id":18238,"href":"https:\/\/lite14.net\/blog\/wp-json\/wp\/v2\/posts\/18237\/revisions\/18238"}],"wp:attachment":[{"href":"https:\/\/lite14.net\/blog\/wp-json\/wp\/v2\/media?parent=18237"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lite14.net\/blog\/wp-json\/wp\/v2\/categories?post=18237"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lite14.net\/blog\/wp-json\/wp\/v2\/tags?post=18237"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}